^
Association details:
Biomarker:CCL5 overexpression
Cancer:Glioblastoma
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

Published date:
07/08/2021
Excerpt:
GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC.
Secondary therapy:
temozolomide
DOI:
10.1038/s41422-021-00528-3